144 related articles for article (PubMed ID: 1691885)
1. AZT (zidovudine) may act postintegrationally to inhibit generation of HIV-1 progeny virus in chronically infected cells.
Rooke R; Tremblay M; Wainberg MA
Virology; 1990 May; 176(1):205-15. PubMed ID: 1691885
[TBL] [Abstract][Full Text] [Related]
2. Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection.
Lambert DM; Bartus H; Fernandez AV; Bratby-Anders C; Leary JJ; Dreyer GB; Metcalf BW; Petteway SR
Antiviral Res; 1993 Aug; 21(4):327-42. PubMed ID: 7692816
[TBL] [Abstract][Full Text] [Related]
3. Sodium pentosan polysulfate (PPS), an anti-HIV agent also exhibits synergism with AZT, lymphoproliferative activity, and virus enhancement.
Anand R; Nayyar S; Galvin TA; Merril CR; Bigelow LB
AIDS Res Hum Retroviruses; 1990 May; 6(5):679-89. PubMed ID: 1694454
[TBL] [Abstract][Full Text] [Related]
4. In vitro assays show a dissociation of reverse transcriptase activity and core antigen (p24) production in two HIV-1 isolates from a patient receiving long-term treatment with zidovudine (ZDV).
Masquelier B; Combeau T; Poveda JD; Delord B; Pellegrin JL; Sallafranque-Andreola ML; Tarrago-Litvak L; Fleury HJ
J Acquir Immune Defic Syndr (1988); 1991; 4(5):499-505. PubMed ID: 1707962
[TBL] [Abstract][Full Text] [Related]
5. Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines.
Poli G; Orenstein JM; Kinter A; Folks TM; Fauci AS
Science; 1989 May; 244(4904):575-7. PubMed ID: 2470148
[TBL] [Abstract][Full Text] [Related]
6. Effect of 3'-azido-3'-deoxythymidine on human immunodeficiency virus type 1 replication in human fetal brain macrophages.
Geleziunas R; Arts EJ; Boulerice F; Goldman H; Wainberg MA
Antimicrob Agents Chemother; 1993 Jun; 37(6):1305-12. PubMed ID: 8392310
[TBL] [Abstract][Full Text] [Related]
7. Modification of human immunodeficiency viral replication by pine cone extracts.
Lai PK; Donovan J; Takayama H; Sakagami H; Tanaka A; Konno K; Nonoyama M
AIDS Res Hum Retroviruses; 1990 Feb; 6(2):205-17. PubMed ID: 1691654
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility to AZT of HIV-1 variants grown in Epstein-Barr virus-transformed B cell lines.
Tremblay M; Wainberg MA
J Infect Dis; 1989 Jul; 160(1):31-6. PubMed ID: 2543710
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human interferon-beta suppresses the replication of HIV and acts synergistically with AZT.
Williams GJ; Colby CB
J Interferon Res; 1989 Dec; 9(6):709-18. PubMed ID: 2514233
[TBL] [Abstract][Full Text] [Related]
10. Inhibition by AZT of HIV-1 replication in acutely infected U-937 cells.
Boulerice F; Wainberg MA
J Leukoc Biol; 1990 Jun; 47(6):498-505. PubMed ID: 2191063
[TBL] [Abstract][Full Text] [Related]
11. Characterization of reverse transcriptase activity and susceptibility to other nucleosides of AZT-resistant variants of HIV-1. Results from the Canadian AZT Multicentre Study.
Wainberg MA; Tremblay M; Rooke R; Blain N; Soudeyns H; Parniak MA; Yao XJ; Li XG; Fanning M; Montaner JS
Ann N Y Acad Sci; 1990; 616():346-55. PubMed ID: 1706573
[No Abstract] [Full Text] [Related]
12. Inhibition of 3'azido-3'deoxythymidine-resistant HIV-1 infection by dehydroepiandrosterone in vitro.
Yang JY; Schwartz A; Henderson EE
Biochem Biophys Res Commun; 1994 Jun; 201(3):1424-32. PubMed ID: 8024587
[TBL] [Abstract][Full Text] [Related]
13. Infection of human monocyte-derived macrophages by human immunodeficiency virus mediated by cell-to-cell transmission.
St Luce S; Arts E; Geleziunas R; Bour S; Wainberg MA
J Med Virol; 1993 Sep; 41(1):71-8. PubMed ID: 7693862
[TBL] [Abstract][Full Text] [Related]
14. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics.
Sundqvist VA; Albert J; Ohlsson E; Hinkula J; Fenyö EM; Wahren B
J Med Virol; 1989 Nov; 29(3):170-5. PubMed ID: 2482339
[TBL] [Abstract][Full Text] [Related]
16. The effect of AZT on in vitro lymphokine-activated killer (LAK) activity in human immunodeficiency virus type-1 (HIV-1) infected individuals.
Stine KC; Tyler DS; Stanley SD; Bartlett JA; Bolognesi DP; Weinhold KJ
Cell Immunol; 1991 Aug; 136(1):165-72. PubMed ID: 1905587
[TBL] [Abstract][Full Text] [Related]
17. Incorporation of 12-methoxydodecanoate into the human immunodeficiency virus 1 gag polyprotein precursor inhibits its proteolytic processing and virus production in a chronically infected human lymphoid cell line.
Bryant ML; Ratner L; Duronio RJ; Kishore NS; Devadas B; Adams SP; Gordon JI
Proc Natl Acad Sci U S A; 1991 Mar; 88(6):2055-9. PubMed ID: 2006142
[TBL] [Abstract][Full Text] [Related]
18. AZT inhibits the transmission of human T cell leukaemia/lymphoma virus type I to adult peripheral blood mononuclear cells in vitro.
Macchi B; Faraoni I; Zhang J; Grelli S; Favalli C; Mastino A; Bonmassar E
J Gen Virol; 1997 May; 78 ( Pt 5)():1007-16. PubMed ID: 9152417
[TBL] [Abstract][Full Text] [Related]
19. Anti-HIV-1 activity of 3'-azido-3'-deoxythymidine (AZT) in primary mononuclear phagocytes.
Beenhouwer DO; Rankin JA; Mellors JW
Antiviral Res; 1992 Jul; 19(1):43-54. PubMed ID: 1444321
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 gag proteins in virions and in infected cell fractions.
Sharova NK; Grigor'ev VB; Bukrinskaya AG
Biomed Sci; 1991; 2(3):279-84. PubMed ID: 1751761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
